Investor Relations

Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).

Share price

0 SEK (0%)

Latest Financial Report 

Interim Report Q2 2024



Q1 2024 Run through

Watch as Nikolaj Sørensen, President and CEO, summarizes the quarter and Orexo's focus going forward. 

Presentation of Q2 2024 - July 17 at 2 pm CET

Listen to the presentation where CEO Nikolaj Sørensen, and CFO Fredrik Järrsten, are presenting the latest development, which is followed by a Q&A.

Latest CEO Comments

JULY 17, 2024

"Strong Zubsolv® recovery and focus on getting OX124 to the US market"

Read the latest CEO comments from Nikolaj Sørensen

Annual General Meeting 

Our shareholders were invited to attend the 2024 Annual General Meeting on April 26. Find out what decisions were taken and other information ahead of the AGM under the Corporate Governance section - AGM

Annual and Sustainability Report 2023

The Annual and Sustainability Report 2023 was published on March 28, at 8 am CET

ESG sustainability investing

Orexo has established a social financing framework

Read more

Key financial figures

Group net revenue

615.3 MSEK
Last Twelve Months, Q323-Q224


23.8 MSEK
Last Twelve Months, Q323-Q224

US Commercial segment EBIT

144.8 MSEK
Last Twelve Months, Q323-Q224

Cash position

139.7 MSEK